董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Meline | 男 | Director | 68 | 122.82万美元 | 0.70 | 2026-03-30 |
| Robert Huffines | 男 | Director | 60 | 7.09万美元 | 4.16 | 2026-03-30 |
| Leon Chen | 男 | Director | 51 | 未披露 | 未持股 | 2026-03-30 |
| Kenneth C. Frazier | 男 | Director | 71 | 6.80万美元 | 18.87 | 2026-03-30 |
| Joshua Wolfe | 男 | Director | 48 | 未披露 | 597.28 | 2026-03-30 |
| Roger M. Perlmutter | 男 | Chair and Chief Executive Officer and Director | 73 | 1294.67万美元 | 289.32 | 2026-03-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Roy Baynes | 男 | Chief Medical Officer | 71 | 161.29万美元 | 19.24 | 2026-03-30 |
| Alfred Bowie | 男 | Chief Financial Officer | 44 | 未披露 | 未持股 | 2026-03-30 |
| Benjamin Thorner | 男 | Chief Business Officer and General Counsel | 55 | 未披露 | 未持股 | 2026-03-30 |
| Michael Klobuchar | 男 | Chief Operating Officer | 50 | 202.13万美元 | 7.01 | 2026-03-30 |
| Roger M. Perlmutter | 男 | Chair and Chief Executive Officer and Director | 73 | 1294.67万美元 | 289.32 | 2026-03-30 |
董事简历
中英对照 | 中文 | 英文- David Meline
-
David Meline，AMGEN，从2014到2019担任Moderna, Inc.首席财务官和执行副总裁。3M公司从2008到2014在多个职位，最近首席财务官和高级副总裁。在他在3M公司的时间之前，Meline先生在通用汽车公司担任了许多领导职务。芝加哥大学，金融管理学硕士，伦敦经济学院，经济学硕士，爱荷华州立大学，机械工程科学学士。
David Meline has extensive leadership experience to Eikon Therapeutics, Inc.'s Board. He currently serves on the Boards of Lonza Group AG (since 2025), HP Inc. (since 2023), and ABB Ltd. (since 2016), and previously served on the Board of Pacific Biosciences from 2023 to 2025. Mr. Meline served as Chief Financial Officer of Moderna Inc. from 2020 to 2022. Prior to that, he was Chief Financial Officer and Executive Vice President at Amgen from 2014 to 2020; and from 2008 to 2014, Mr. Meline was Chief Financial Officer of 3M Company. Earlier in his career, Mr. Meline spent more than 20 years in a variety of finance and management roles at General Motors Company. - David Meline，AMGEN，从2014到2019担任Moderna, Inc.首席财务官和执行副总裁。3M公司从2008到2014在多个职位，最近首席财务官和高级副总裁。在他在3M公司的时间之前，Meline先生在通用汽车公司担任了许多领导职务。芝加哥大学，金融管理学硕士，伦敦经济学院，经济学硕士，爱荷华州立大学，机械工程科学学士。
- David Meline has extensive leadership experience to Eikon Therapeutics, Inc.'s Board. He currently serves on the Boards of Lonza Group AG (since 2025), HP Inc. (since 2023), and ABB Ltd. (since 2016), and previously served on the Board of Pacific Biosciences from 2023 to 2025. Mr. Meline served as Chief Financial Officer of Moderna Inc. from 2020 to 2022. Prior to that, he was Chief Financial Officer and Executive Vice President at Amgen from 2014 to 2020; and from 2008 to 2014, Mr. Meline was Chief Financial Officer of 3M Company. Earlier in his career, Mr. Meline spent more than 20 years in a variety of finance and management roles at General Motors Company.
- Robert Huffines
-
Robert Huffines自2013年12月以来一直担任我们的董事会成员。Huffines先生于1991年加入全球领先的金融服务公司摩根大通（J.P.Morgan），目前担任投资银行业务全球董事长，自2017年2月起担任该职位。在摩根大通的整个职业生涯中，Huffines先生担任过多个领导职位，包括2002年至2010年担任全球梦百合投资银行集团联席主管，2011年至2017年1月担任副董事长。Huffines先生在弗吉尼亚大学（University of Virginia）获得工商管理硕士学位，在北卡罗莱纳大学（University of North Carolina）获得工商管理学士学位。
Robert Huffines has served as a member of board of directors since 2023. Mr. Huffines joined J.P. Morgan Chase & Co., or J.P. Morgan, a leading global financial services firm, in 1992 and retired in 2024 as the Global Chairman of Investment Banking, a position he has held since February 2017. Throughout his career at J.P. Morgan, Mr. Huffines has held various leadership positions, including serving as of the Global Healthcare Investment Banking Group from 2002 to 2010 and Vice Chairman from 2011 to January 2017. Mr. Huffines also served as a member of the board of directors of Solid Biosciences Inc. (Nasdaq: SLDB) from December 2013 to June 2023 and as a member of the board of directors of Walgreens Boots Alliance, Inc. (Nasdaq: WBA) from January 2024 to August 2025. Mr. Huffines currently serves as a member of the board of directors at Insulet Corporation (Nasdaq: PODD), Becton, Dickinson and Company (NYSE: BDX), Nextech Invest, and the Hastings Center for Biomedical Ethics. Mr. Huffines received a M.B.A. from the University of Virginia and a B.A. from the University of North Carolina. - Robert Huffines自2013年12月以来一直担任我们的董事会成员。Huffines先生于1991年加入全球领先的金融服务公司摩根大通（J.P.Morgan），目前担任投资银行业务全球董事长，自2017年2月起担任该职位。在摩根大通的整个职业生涯中，Huffines先生担任过多个领导职位，包括2002年至2010年担任全球梦百合投资银行集团联席主管，2011年至2017年1月担任副董事长。Huffines先生在弗吉尼亚大学（University of Virginia）获得工商管理硕士学位，在北卡罗莱纳大学（University of North Carolina）获得工商管理学士学位。
- Robert Huffines has served as a member of board of directors since 2023. Mr. Huffines joined J.P. Morgan Chase & Co., or J.P. Morgan, a leading global financial services firm, in 1992 and retired in 2024 as the Global Chairman of Investment Banking, a position he has held since February 2017. Throughout his career at J.P. Morgan, Mr. Huffines has held various leadership positions, including serving as of the Global Healthcare Investment Banking Group from 2002 to 2010 and Vice Chairman from 2011 to January 2017. Mr. Huffines also served as a member of the board of directors of Solid Biosciences Inc. (Nasdaq: SLDB) from December 2013 to June 2023 and as a member of the board of directors of Walgreens Boots Alliance, Inc. (Nasdaq: WBA) from January 2024 to August 2025. Mr. Huffines currently serves as a member of the board of directors at Insulet Corporation (Nasdaq: PODD), Becton, Dickinson and Company (NYSE: BDX), Nextech Invest, and the Hastings Center for Biomedical Ethics. Mr. Huffines received a M.B.A. from the University of Virginia and a B.A. from the University of North Carolina.
- Leon Chen
-
Leon Chen自2019年起担任Eikon Therapeutics，Inc.董事会成员。2016年1月-2022年11月担任LogicBio医疗，Inc.（纳斯达克：LOGC）董事会成员。陈博士是医疗保健投资公司The Column Group的合伙人，自2019年10月以来一直受雇于该公司。在加入Column Group之前，陈博士曾于2013年6月至2019年9月担任医疗投资公司OrbiMed Advisors LLC的风险合伙人。陈博士目前在几家私营生命科学公司的董事会任职。在过去五年内，陈博士还曾在Nurix Therapeutics, Inc.（纳斯达克：NRIX）的董事会任职。陈博士拥有斯坦福大学医学院分子药理学博士学位、斯坦福大学商学院工商管理硕士学位和加州大学伯克利分校生物化学学士学位。
Leon Chen has served as a member of Eikon Therapeutics, Inc.'s board of directors since 2019. He served as a member of the board of directors of LogicBio Therapeutics, Inc. (Nasdaq: LOGC) from January 2016 to November 2022. Dr. Chen is a partner at The Column Group, a healthcare investment firm, where he has been employed since October 2019. Prior to joining The Column Group, Dr. Chen was a venture partner at OrbiMed Advisors LLC, a healthcare investment firm, from June 2013 to September 2019. Dr. Chen currently serves on the boards of directors of several privately held life sciences companies. Within the past five years, Dr. Chen also served on the board of directors of Nurix Therapeutics, Inc. (Nasdaq: NRIX). Dr. Chen holds a Ph.D. in Molecular Pharmacology from the Stanford School of Medicine, an M.B.A. from the Stanford Graduate School of Business, and a B.A. in Biochemistry from U.C. Berkeley. - Leon Chen自2019年起担任Eikon Therapeutics，Inc.董事会成员。2016年1月-2022年11月担任LogicBio医疗，Inc.（纳斯达克：LOGC）董事会成员。陈博士是医疗保健投资公司The Column Group的合伙人，自2019年10月以来一直受雇于该公司。在加入Column Group之前，陈博士曾于2013年6月至2019年9月担任医疗投资公司OrbiMed Advisors LLC的风险合伙人。陈博士目前在几家私营生命科学公司的董事会任职。在过去五年内，陈博士还曾在Nurix Therapeutics, Inc.（纳斯达克：NRIX）的董事会任职。陈博士拥有斯坦福大学医学院分子药理学博士学位、斯坦福大学商学院工商管理硕士学位和加州大学伯克利分校生物化学学士学位。
- Leon Chen has served as a member of Eikon Therapeutics, Inc.'s board of directors since 2019. He served as a member of the board of directors of LogicBio Therapeutics, Inc. (Nasdaq: LOGC) from January 2016 to November 2022. Dr. Chen is a partner at The Column Group, a healthcare investment firm, where he has been employed since October 2019. Prior to joining The Column Group, Dr. Chen was a venture partner at OrbiMed Advisors LLC, a healthcare investment firm, from June 2013 to September 2019. Dr. Chen currently serves on the boards of directors of several privately held life sciences companies. Within the past five years, Dr. Chen also served on the board of directors of Nurix Therapeutics, Inc. (Nasdaq: NRIX). Dr. Chen holds a Ph.D. in Molecular Pharmacology from the Stanford School of Medicine, an M.B.A. from the Stanford Graduate School of Business, and a B.A. in Biochemistry from U.C. Berkeley.
- Kenneth C. Frazier
-
Kenneth C. Frazier自2022年起担任董事会成员。弗雷泽先生是General Catalyst的Health Assurance计划的主席。弗雷泽先生专注于投资和合作伙伴关系，并为建立公司的创始人提供指导，这些公司的定位是通过协作创新来改变医疗保健产业。弗雷泽先生是默沙东董事会前任执行主席，此前他在2011年至2021年担任默沙东总裁兼首席执行官的长达十年的任期内退休。Frazier先生于1992年加入默沙东，担任的职务越来越重要，包括总法律顾问和总裁。在加入默沙东之前，弗雷泽先生是费城Faegre Drinker Biddle & Reath LLP律师事务所的合伙人。弗雷泽先生的贡献，特别是在法律、BINCE和人道主义领域的贡献，得到了广泛认可。他是OneTen的联合创始人和联合主席，OneTen是一个由致力于提升技能、招聘和推动100万美国黑人进入家庭污点工作的主要组织组成的联盟。除了Eikon，弗雷泽先生还是General Catalyst投资组合公司Paradigm Health的董事会成员，以及众多非营利组织，包括国家宪法中心、宾夕法尼亚州费城的基石基督教学院、病态的康奈尔医学和史密森学会的非裔美国人历史与文化全国成员咨询委员会。Frazier先生还是美国艺术与科学院、美国哲学学会、BINCE理事会、美国法律学会理事会、美国律师协会的成员，以及费城内科医生学院的研究员。此外，弗雷泽先生是法律服务公司领导人委员会的共同主席。作为社会正义和经济煽动的坚定倡导者，弗雷泽先生是数字奖项和荣誉的获得者，包括反诽谤联盟笼子反仇恨奖、哥伦比亚Biness学校的Botwinick Biness伦理学奖、耶鲁大学管理学院的Legend in Leadership奖、全国有色人种协进会法律辩护和教育基金全国平等JTice奖，以及全国少数民族质量论坛的终身成就奖。2018年，弗雷泽先生被《财富》杂志评为全球最伟大领袖之一，也被《时代》杂志评为100位最具影响力人物之一。2019年，他成为福布斯医疗保健终身成就奖的首位获得者。2021年，他的同行们将他评为《首席执行官》杂志的年度首席执行官。Frazier先生拥有宾夕法尼亚州立大学学士学位和哈佛法学院法学博士学位。
Kenneth C. Frazier has served as a member of Eikon Therapeutics, Inc.'s board of directors since 2022. Mr. Frazier is Chairman of General Catalyst's Health Assurance initiatives. Mr. Frazier focuses on investments and partnerships and providing mentorship to founders building companies that are well positioned to transform the healthcare industry through collaborative innovation. Mr. Frazier is the former executive chairman of the board of directors of Merck, following his retirement from a decade long tenure as the Merck's President and Chief Executive Officer from 2011 to 2021. Mr. Frazier joined Merck in 1992 and held positions of increasing responsibility, including general counsel and president. Prior to joining Merck, Mr. Frazier was a partner with the Philadelphia law firm of Faegre Drinker Biddle & Reath LLP. Mr. Frazier's contributions, especially in the legal, business and humanitarian fields, have been widely recognized. He is co founder and co chair of OneTen, a coalition of leading organizations committed to upskilling, hiring, and promoting one million Black Americans into family sustaining jobs. In 2019, he became the first recipient of the Forbes Lifetime Achievement Award for Healthcare. In 2021, his peers named him Chief Executive magazine's CEO of the Year. Mr. Frazier holds a bachelor's degree from Pennsylvania State University and a J.D. from Harvard Law School. - Kenneth C. Frazier自2022年起担任董事会成员。弗雷泽先生是General Catalyst的Health Assurance计划的主席。弗雷泽先生专注于投资和合作伙伴关系，并为建立公司的创始人提供指导，这些公司的定位是通过协作创新来改变医疗保健产业。弗雷泽先生是默沙东董事会前任执行主席，此前他在2011年至2021年担任默沙东总裁兼首席执行官的长达十年的任期内退休。Frazier先生于1992年加入默沙东，担任的职务越来越重要，包括总法律顾问和总裁。在加入默沙东之前，弗雷泽先生是费城Faegre Drinker Biddle & Reath LLP律师事务所的合伙人。弗雷泽先生的贡献，特别是在法律、BINCE和人道主义领域的贡献，得到了广泛认可。他是OneTen的联合创始人和联合主席，OneTen是一个由致力于提升技能、招聘和推动100万美国黑人进入家庭污点工作的主要组织组成的联盟。除了Eikon，弗雷泽先生还是General Catalyst投资组合公司Paradigm Health的董事会成员，以及众多非营利组织，包括国家宪法中心、宾夕法尼亚州费城的基石基督教学院、病态的康奈尔医学和史密森学会的非裔美国人历史与文化全国成员咨询委员会。Frazier先生还是美国艺术与科学院、美国哲学学会、BINCE理事会、美国法律学会理事会、美国律师协会的成员，以及费城内科医生学院的研究员。此外，弗雷泽先生是法律服务公司领导人委员会的共同主席。作为社会正义和经济煽动的坚定倡导者，弗雷泽先生是数字奖项和荣誉的获得者，包括反诽谤联盟笼子反仇恨奖、哥伦比亚Biness学校的Botwinick Biness伦理学奖、耶鲁大学管理学院的Legend in Leadership奖、全国有色人种协进会法律辩护和教育基金全国平等JTice奖，以及全国少数民族质量论坛的终身成就奖。2018年，弗雷泽先生被《财富》杂志评为全球最伟大领袖之一，也被《时代》杂志评为100位最具影响力人物之一。2019年，他成为福布斯医疗保健终身成就奖的首位获得者。2021年，他的同行们将他评为《首席执行官》杂志的年度首席执行官。Frazier先生拥有宾夕法尼亚州立大学学士学位和哈佛法学院法学博士学位。
- Kenneth C. Frazier has served as a member of Eikon Therapeutics, Inc.'s board of directors since 2022. Mr. Frazier is Chairman of General Catalyst's Health Assurance initiatives. Mr. Frazier focuses on investments and partnerships and providing mentorship to founders building companies that are well positioned to transform the healthcare industry through collaborative innovation. Mr. Frazier is the former executive chairman of the board of directors of Merck, following his retirement from a decade long tenure as the Merck's President and Chief Executive Officer from 2011 to 2021. Mr. Frazier joined Merck in 1992 and held positions of increasing responsibility, including general counsel and president. Prior to joining Merck, Mr. Frazier was a partner with the Philadelphia law firm of Faegre Drinker Biddle & Reath LLP. Mr. Frazier's contributions, especially in the legal, business and humanitarian fields, have been widely recognized. He is co founder and co chair of OneTen, a coalition of leading organizations committed to upskilling, hiring, and promoting one million Black Americans into family sustaining jobs. In 2019, he became the first recipient of the Forbes Lifetime Achievement Award for Healthcare. In 2021, his peers named him Chief Executive magazine's CEO of the Year. Mr. Frazier holds a bachelor's degree from Pennsylvania State University and a J.D. from Harvard Law School.
- Joshua Wolfe
-
Joshua Wolfe自2022年起担任Eikon Therapeutics，Inc.董事会成员。Wolfe co先生创立了Lux Capital，还曾担任Aera Therapeutics，Inc.的董事，自2022年4月起，Cajal Neuroscience Inc.自2022年3月起，EvolutionaryScale，PBC，自2023年9月起，Gandeeva Therapeutics，Inc.自2022年3月起，Impulse Labs，Inc.自2022年9月起，Kallyope，Inc.自2022年3月起，Osmo Labs，PBC自2022年7月起，Variant Bio，Inc.自2018年11月起，Yemaya，Inc.自2024年4月起，并帮助领导Lux Capital对Anduril Industries，Inc.、Echodyne Corp.、Planet Labs PBC（NYSE：PL）、Hadrian Automation，Inc.、Tangible Play Inc.和National ResInc.他是创始投资者，曾于2012年8月至2025年3月与比尔·盖茨一起在Kymeta公司担任董事会成员，为高速全球卫星和空间通信制造尖端天线。Wolfe先生是西屋电气的准决赛选手和出版科学家。他之前曾在Salomon Smith Barney Inc.从事投资银行工作，并在Merrill Lynch，Pierce，Fenner & Smith Incorporated从事资本市场工作。2008年，Wolfe先生共同创立并资助了Kurion，Inc。Wolfe先生是《福布斯》的专栏作家，也是《福布斯/Wolfe新兴技术报告》的编辑。他曾受邀到白宫和国会山就纳米技术和新兴技术提供建议，并在麻省理工学院、哈佛大学、耶鲁大学、康奈尔大学、哥伦比亚大学和纽约大学担任讲师。他是外交关系委员会的长期成员、圣达菲研究所的受托人和康尼岛预科特许学校的主席。Wolfe先生拥有康奈尔大学经济学和金融学学士学位。
Joshua Wolfe has served as a member of Eikon Therapeutics, Inc.'s board of directors since 2022. Mr. Wolfe co founded Lux Capital and has also been a director at Aera Therapeutics, Inc. since April 2022, Cajal Neuroscience Inc. since March 2022, EvolutionaryScale, PBC, since September 2023, Gandeeva Therapeutics, Inc. since March 2022, Impulse Labs, Inc. since September 2022, Kallyope, Inc. since March 2022, Osmo Labs, PBC since July 2022, Variant Bio, Inc. since November 2018, and Yemaya, Inc. since April 2024, and helped lead Lux Capital's investments in Anduril Industries, Inc., Echodyne Corp., Planet Labs PBC (NYSE: PL), Hadrian Automation, Inc., Tangible Play Inc., and National Resilience, Inc. He is a founding investor and was a board member with Bill Gates in Kymeta Corporation from August 2012 to March 2025, making cutting edge antennas for high speed global satellite and space communications. Mr. Wolfe is a Westinghouse semi finalist and published scientist. He previously worked in investment banking at Salomon Smith Barney Inc. and in capital markets at Merrill Lynch, Pierce, Fenner & Smith Incorporated. In 2008, Mr. Wolfe co founded and funded Kurion, Inc. Mr. Wolfe is a columnist with Forbes and Editor for the Forbes/Wolfe Emerging Tech Report. He has been invited to The White House and Capitol Hill to advise on nanotechnology and emerging technologies and is a lecturer at the Massachusetts Institute of Technology, Harvard, Yale, Cornell, Columbia, and New York University. He is a term member at The Council on Foreign Relations, a Trustee at the Santa Fe Institute and Chairman of Coney Island Prep charter school. Mr. Wolfe holds a B.S. in Economics and Finance from Cornell University. - Joshua Wolfe自2022年起担任Eikon Therapeutics，Inc.董事会成员。Wolfe co先生创立了Lux Capital，还曾担任Aera Therapeutics，Inc.的董事，自2022年4月起，Cajal Neuroscience Inc.自2022年3月起，EvolutionaryScale，PBC，自2023年9月起，Gandeeva Therapeutics，Inc.自2022年3月起，Impulse Labs，Inc.自2022年9月起，Kallyope，Inc.自2022年3月起，Osmo Labs，PBC自2022年7月起，Variant Bio，Inc.自2018年11月起，Yemaya，Inc.自2024年4月起，并帮助领导Lux Capital对Anduril Industries，Inc.、Echodyne Corp.、Planet Labs PBC（NYSE：PL）、Hadrian Automation，Inc.、Tangible Play Inc.和National ResInc.他是创始投资者，曾于2012年8月至2025年3月与比尔·盖茨一起在Kymeta公司担任董事会成员，为高速全球卫星和空间通信制造尖端天线。Wolfe先生是西屋电气的准决赛选手和出版科学家。他之前曾在Salomon Smith Barney Inc.从事投资银行工作，并在Merrill Lynch，Pierce，Fenner & Smith Incorporated从事资本市场工作。2008年，Wolfe先生共同创立并资助了Kurion，Inc。Wolfe先生是《福布斯》的专栏作家，也是《福布斯/Wolfe新兴技术报告》的编辑。他曾受邀到白宫和国会山就纳米技术和新兴技术提供建议，并在麻省理工学院、哈佛大学、耶鲁大学、康奈尔大学、哥伦比亚大学和纽约大学担任讲师。他是外交关系委员会的长期成员、圣达菲研究所的受托人和康尼岛预科特许学校的主席。Wolfe先生拥有康奈尔大学经济学和金融学学士学位。
- Joshua Wolfe has served as a member of Eikon Therapeutics, Inc.'s board of directors since 2022. Mr. Wolfe co founded Lux Capital and has also been a director at Aera Therapeutics, Inc. since April 2022, Cajal Neuroscience Inc. since March 2022, EvolutionaryScale, PBC, since September 2023, Gandeeva Therapeutics, Inc. since March 2022, Impulse Labs, Inc. since September 2022, Kallyope, Inc. since March 2022, Osmo Labs, PBC since July 2022, Variant Bio, Inc. since November 2018, and Yemaya, Inc. since April 2024, and helped lead Lux Capital's investments in Anduril Industries, Inc., Echodyne Corp., Planet Labs PBC (NYSE: PL), Hadrian Automation, Inc., Tangible Play Inc., and National Resilience, Inc. He is a founding investor and was a board member with Bill Gates in Kymeta Corporation from August 2012 to March 2025, making cutting edge antennas for high speed global satellite and space communications. Mr. Wolfe is a Westinghouse semi finalist and published scientist. He previously worked in investment banking at Salomon Smith Barney Inc. and in capital markets at Merrill Lynch, Pierce, Fenner & Smith Incorporated. In 2008, Mr. Wolfe co founded and funded Kurion, Inc. Mr. Wolfe is a columnist with Forbes and Editor for the Forbes/Wolfe Emerging Tech Report. He has been invited to The White House and Capitol Hill to advise on nanotechnology and emerging technologies and is a lecturer at the Massachusetts Institute of Technology, Harvard, Yale, Cornell, Columbia, and New York University. He is a term member at The Council on Foreign Relations, a Trustee at the Santa Fe Institute and Chairman of Coney Island Prep charter school. Mr. Wolfe holds a B.S. in Economics and Finance from Cornell University.
- Roger M. Perlmutter
-
Roger M. Perlmutter自2013年4月起担任默克制药公司负责默克研究实验室的执行副总裁及总裁，管理全球公司的研究和开发。于2001年1月成为安进公司研发执行副总裁。从1999年7月到2000年12月，他担任Merck研究实验室全球基础研究和临床前开发的执行副总裁。从1999年2月到1999年7月，他担任默克研究实验室的执行副总裁，从1997年2月到1999年1月担任默克研究实验室的高级副总裁。从1989年5月到1997年1月，他也是华盛顿大学免疫学系的主席，从1991年1月到1997年1月，华盛顿大学免疫、生物化学和医学系的教授。从1984年7月到1997年1月，他担任华盛顿大学霍华德休斯医学研究所的研究员。他目前任职于StemCells, Inc.的董事会。
Roger M. Perlmutter has served as Chief Executive Officer and Chair and a member of board of directors since 2021. Dr. Perlmutter is a highly accomplished industry and academic leader with more than 35 years of experience. Prior to joining Eikon Therapeutics, Inc., Dr. Perlmutter was Executive Vice President of Merck and President of Merck Research Laboratories, or MRL, from 2013 to 2020, where he supervised the discovery and development of numerous lifesaving medicines including pembrolizumab, Merck's foundational immuno oncology therapeutic. Before his time at Merck, Dr. Perlmutter spent twelve years as Executive Vice President and Head of Research and Development at Amgen, where he supervised the development of important biopharmaceuticals for the treatment of osteoporosis and cancer related bone disease and for the reduction of hypercholesterolemia related cardiovascular risk. Prior to Amgen, Dr. Perlmutter served as Executive Vice President of Basic and Preclinical Research at MRL from 1997 to 2001. Prior to assuming leadership roles in the industry, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry, and Medicine at the University of Washington, Seattle and also served as Chairman of its Department of Immunology, where he was at the same time an investigator of the Howard Hughes Medical Institute. His research focused on understanding the signaling pathways that control lymphocyte activation. Prior to his role at the University of Washington, he was a lecturer in the Division of Biology at the California Institute of Technology, Pasadena. Dr. Perlmutter is an elected member of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, and both a distinguished fellow and past president of the American Association of Immunologists. Dr. Perlmutter currently serves on the board of directors at Insitro, Inc. and NGM Biopharmaceuticals, Inc. Dr. Perlmutter holds an M.D. and a Ph.D. from Washington University in St. Louis and a bachelor's degree from Reed College. - Roger M. Perlmutter自2013年4月起担任默克制药公司负责默克研究实验室的执行副总裁及总裁，管理全球公司的研究和开发。于2001年1月成为安进公司研发执行副总裁。从1999年7月到2000年12月，他担任Merck研究实验室全球基础研究和临床前开发的执行副总裁。从1999年2月到1999年7月，他担任默克研究实验室的执行副总裁，从1997年2月到1999年1月担任默克研究实验室的高级副总裁。从1989年5月到1997年1月，他也是华盛顿大学免疫学系的主席，从1991年1月到1997年1月，华盛顿大学免疫、生物化学和医学系的教授。从1984年7月到1997年1月，他担任华盛顿大学霍华德休斯医学研究所的研究员。他目前任职于StemCells, Inc.的董事会。
- Roger M. Perlmutter has served as Chief Executive Officer and Chair and a member of board of directors since 2021. Dr. Perlmutter is a highly accomplished industry and academic leader with more than 35 years of experience. Prior to joining Eikon Therapeutics, Inc., Dr. Perlmutter was Executive Vice President of Merck and President of Merck Research Laboratories, or MRL, from 2013 to 2020, where he supervised the discovery and development of numerous lifesaving medicines including pembrolizumab, Merck's foundational immuno oncology therapeutic. Before his time at Merck, Dr. Perlmutter spent twelve years as Executive Vice President and Head of Research and Development at Amgen, where he supervised the development of important biopharmaceuticals for the treatment of osteoporosis and cancer related bone disease and for the reduction of hypercholesterolemia related cardiovascular risk. Prior to Amgen, Dr. Perlmutter served as Executive Vice President of Basic and Preclinical Research at MRL from 1997 to 2001. Prior to assuming leadership roles in the industry, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry, and Medicine at the University of Washington, Seattle and also served as Chairman of its Department of Immunology, where he was at the same time an investigator of the Howard Hughes Medical Institute. His research focused on understanding the signaling pathways that control lymphocyte activation. Prior to his role at the University of Washington, he was a lecturer in the Division of Biology at the California Institute of Technology, Pasadena. Dr. Perlmutter is an elected member of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, and both a distinguished fellow and past president of the American Association of Immunologists. Dr. Perlmutter currently serves on the board of directors at Insitro, Inc. and NGM Biopharmaceuticals, Inc. Dr. Perlmutter holds an M.D. and a Ph.D. from Washington University in St. Louis and a bachelor's degree from Reed College.
高管简历
中英对照 | 中文 | 英文- Roy Baynes
Roy Baynes自2018年7月起担任我们的董事会成员。Baynes博士自2013年12月起担任默克研究实验室（Merck Research Laboratories，NYSE:MRK）全球临床开发高级副总裁，主管和首席医疗官，该公司是一家生物制药公司。在此之前，Baynes博士于2012年1月至2013年12月担任生物技术公司Gilead Sciences Inc.（纳斯达克市场代码:GILD）肿瘤学、炎症和呼吸治疗高级副总裁，并担任安进公司（纳斯达克市场代码:AMGN）Vice President全球开发和治疗领域血液肿瘤学主管，一家生物制药公司，从2002年到2012年。Baynes博士自2018年9月起担任生物制药公司AtaraBiotherapeutics，Inc.（Nasdsq:ATRA）的董事，自2016年7月起担任生物制药公司Retrophin，Inc.（Nasdaq:RTRX）的董事。Baynes博士拥有南非约翰内斯堡the University of the Witwatersrand的医学博士学位和博士学位。
Roy Baynes has served as Executive Vice President and Chief Medical Officer since July 2022 and was a compensated consultant for Eikon Therapeutics, Inc. from April 2022 to July 2022. Before joining Eikon Therapeutics, Inc., Dr. Baynes served as Chief Medical Officer, Senior Vice President and Head of Global Clinical Development at Merck from 2013 to 2022, where he helped Merck become a leading oncology and global healthcare company. Dr. Baynes also previously served as Senior Vice President of Oncology, Inflammation, and Respiratory Therapeutics at Gilead Sciences, Inc. from 2012 to 2013, which was preceded by his service at Amgen, as Vice President of Global Clinical Development and Therapeutic Area Head for hematology/oncology. Before joining Amgen in 2002, Dr. Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute designated Comprehensive Cancer Center, at Wayne State University. Dr. Baynes currently serves on the board of directors at Natera, Inc. (Nasdaq: NTRA), Travere Therapeutics, Inc. (Nasdaq: TVTX), CatalYm GmbH, Aardvark Therapeutics, Inc. (Nasdaq: AARD), Nurix Therapeutics, Inc. (Nasdaq: NRIX), and Adcendo ApS, and is a compensated advisor to Decheng Capital, CatalYm GmbH, and Adcendo ApS. Dr. Baynes has received numerous awards for his activities as a physician and scientist. Dr. Baynes holds a medical degree and a doctor of philosophy from the University of the Witwatersrand in South Africa and completed his medical training in the Department of Hematology and Oncology at Johannesburg Hospital.- Roy Baynes自2018年7月起担任我们的董事会成员。Baynes博士自2013年12月起担任默克研究实验室（Merck Research Laboratories，NYSE:MRK）全球临床开发高级副总裁，主管和首席医疗官，该公司是一家生物制药公司。在此之前，Baynes博士于2012年1月至2013年12月担任生物技术公司Gilead Sciences Inc.（纳斯达克市场代码:GILD）肿瘤学、炎症和呼吸治疗高级副总裁，并担任安进公司（纳斯达克市场代码:AMGN）Vice President全球开发和治疗领域血液肿瘤学主管，一家生物制药公司，从2002年到2012年。Baynes博士自2018年9月起担任生物制药公司AtaraBiotherapeutics，Inc.（Nasdsq:ATRA）的董事，自2016年7月起担任生物制药公司Retrophin，Inc.（Nasdaq:RTRX）的董事。Baynes博士拥有南非约翰内斯堡the University of the Witwatersrand的医学博士学位和博士学位。
- Roy Baynes has served as Executive Vice President and Chief Medical Officer since July 2022 and was a compensated consultant for Eikon Therapeutics, Inc. from April 2022 to July 2022. Before joining Eikon Therapeutics, Inc., Dr. Baynes served as Chief Medical Officer, Senior Vice President and Head of Global Clinical Development at Merck from 2013 to 2022, where he helped Merck become a leading oncology and global healthcare company. Dr. Baynes also previously served as Senior Vice President of Oncology, Inflammation, and Respiratory Therapeutics at Gilead Sciences, Inc. from 2012 to 2013, which was preceded by his service at Amgen, as Vice President of Global Clinical Development and Therapeutic Area Head for hematology/oncology. Before joining Amgen in 2002, Dr. Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute designated Comprehensive Cancer Center, at Wayne State University. Dr. Baynes currently serves on the board of directors at Natera, Inc. (Nasdaq: NTRA), Travere Therapeutics, Inc. (Nasdaq: TVTX), CatalYm GmbH, Aardvark Therapeutics, Inc. (Nasdaq: AARD), Nurix Therapeutics, Inc. (Nasdaq: NRIX), and Adcendo ApS, and is a compensated advisor to Decheng Capital, CatalYm GmbH, and Adcendo ApS. Dr. Baynes has received numerous awards for his activities as a physician and scientist. Dr. Baynes holds a medical degree and a doctor of philosophy from the University of the Witwatersrand in South Africa and completed his medical training in the Department of Hematology and Oncology at Johannesburg Hospital.
- Alfred Bowie
Alfred Bowie自2021年起担任首席财务官，领导财务、公司规划、投资者关系和采购职能。在加入之前，Bowie博士负责监督基因组诊断公司Veracyte, Inc.或Veracyte的战略和运营职能，包括2019年至2021年的企业和BINCE发展、战略规划和销售运营。在Veracyte，他领导了与拜耳公司、阿斯利康公司和强生公司等公司的合作，并策划了多项收购活动。在加入Veracyte之前，Bowie博士于2016年至2019年在罗氏集团的全资子公司Foundation Medicine, Inc.担任企业发展和战略高级总监，在那里他领导了战略规划、企业发展和竞争情报。他还曾在Tecan Group和丹纳赫公司担任企业和BINCE开发职位。鲍伊博士拥有加州大学伯克利分校合成有机化学博士学位和北卡罗来纳州戴维森学院化学学士学位。
Alfred Bowie has served as Chief Financial Officer since 2021, where he leads the finance, corporate planning, investor relations, and procurement functions. Prior to joining Eikon Therapeutics, Inc., Dr. Bowie oversaw strategic and operational functions at the genomic diagnostics company, Veracyte, Inc., or Veracyte, including corporate and business development, strategic planning and sales operations from 2019 to 2021. At Veracyte, he led collaborations with companies such as Bayer AG, AstraZeneca plc, and Johnson & Johnson, Inc., and orchestrated multiple acquisitions. Before joining Veracyte, Dr. Bowie was Senior Director of Corporate Development and Strategy at Foundation Medicine, Inc., a wholly owned subsidiary of The Roche Group from 2016 to 2019, where he led strategic planning, corporate development, and competitive intelligence. He also served in corporate and business development positions at Tecan Group and Danaher Corporation. Dr. Bowie holds a doctorate in synthetic organic chemistry from the University of California, Berkeley and a bachelor's degree in chemistry from Davidson College in North Carolina.- Alfred Bowie自2021年起担任首席财务官，领导财务、公司规划、投资者关系和采购职能。在加入之前，Bowie博士负责监督基因组诊断公司Veracyte, Inc.或Veracyte的战略和运营职能，包括2019年至2021年的企业和BINCE发展、战略规划和销售运营。在Veracyte，他领导了与拜耳公司、阿斯利康公司和强生公司等公司的合作，并策划了多项收购活动。在加入Veracyte之前，Bowie博士于2016年至2019年在罗氏集团的全资子公司Foundation Medicine, Inc.担任企业发展和战略高级总监，在那里他领导了战略规划、企业发展和竞争情报。他还曾在Tecan Group和丹纳赫公司担任企业和BINCE开发职位。鲍伊博士拥有加州大学伯克利分校合成有机化学博士学位和北卡罗来纳州戴维森学院化学学士学位。
- Alfred Bowie has served as Chief Financial Officer since 2021, where he leads the finance, corporate planning, investor relations, and procurement functions. Prior to joining Eikon Therapeutics, Inc., Dr. Bowie oversaw strategic and operational functions at the genomic diagnostics company, Veracyte, Inc., or Veracyte, including corporate and business development, strategic planning and sales operations from 2019 to 2021. At Veracyte, he led collaborations with companies such as Bayer AG, AstraZeneca plc, and Johnson & Johnson, Inc., and orchestrated multiple acquisitions. Before joining Veracyte, Dr. Bowie was Senior Director of Corporate Development and Strategy at Foundation Medicine, Inc., a wholly owned subsidiary of The Roche Group from 2016 to 2019, where he led strategic planning, corporate development, and competitive intelligence. He also served in corporate and business development positions at Tecan Group and Danaher Corporation. Dr. Bowie holds a doctorate in synthetic organic chemistry from the University of California, Berkeley and a bachelor's degree in chemistry from Davidson College in North Carolina.
- Benjamin Thorner
Benjamin Thorner自2021年起担任总法律顾问和首席BINCE官，负责监督Eikon的所有法律事务和交易制定。在加入Eikon之前，Thorner先生曾于2014年至2021年担任MRL高级副总裁兼Biness开发和许可负责人。在担任该职务期间，索纳先生监督了所有促成该管道的交易制定活动，其中包括发现、技术、临床前和临床阶段交易，以及MRL风险投资基金。在加入默沙东之前，Thorner先生曾于2009年至2014年在诺华生物医学研究所担任交易、战略联盟主管，领导一个交易谈判人员团队，负责诺华公司（Novartis AG）或诺华（Novartis）的治疗管线的概念交易预验证。在加入诺华公司之前，Thorner先生曾于2003年至2009年在其法律和许可组织中担任安进的责任越来越大的职位。Thorner先生目前在Acesion Pharma AP担任董事会成员。在加入工业之前，Thorner先生在私人执业部门工作，就战略知识产权问题、许可协议、战略联盟和其他公司交易提供咨询。此外，他还担任美国联邦巡回上诉委员会尊敬的Randall R. Rader的书记员。Thorner先生拥有弗吉尼亚大学的法学博士和生物学硕士学位以及乔治梅森大学的学士学位。
Benjamin Thorner has served as General Counsel and Chief Business Officer since 2021, overseeing all legal matters and deal making for Eikon. Prior to joining Eikon, Mr. Thorner served as Senior Vice President and Head of Business Development and Licensing for MRL from 2014 to 2021. In that role, Mr. Thorner supervised all deal making activities that contributed to the pipeline, which included discovery, technologies, preclinical and clinical stage deals, as well as the MRL Ventures Fund. Before Merck, Mr. Thorner served as Head of Transactions, Strategic Alliances at the Novartis Institutes for BioMedical Research from 2009 to 2014, leading a team of deal negotiators responsible for pre proof of concept deals for Novartis AG's, or Novartis', therapeutics pipeline. Prior to Novartis, Mr. Thorner held positions of increasing responsibility with Amgen in their legal and licensing organizations from 2003 to 2009. Mr. Thorner currently serves on the board of directors at Acesion Pharma ApS. Before joining the industry, Mr. Thorner worked in private practice providing counsel on strategic intellectual property issues, licensing agreements, strategic alliances, and other corporate transactions. In addition, he served as clerk to the Honorable Randall R. Rader, U.S. Court of Appeals for the Federal Circuit. Mr. Thorner holds a J.D. and master's degree in biology from the University of Virginia and a bachelor's degree from George Mason University.- Benjamin Thorner自2021年起担任总法律顾问和首席BINCE官，负责监督Eikon的所有法律事务和交易制定。在加入Eikon之前，Thorner先生曾于2014年至2021年担任MRL高级副总裁兼Biness开发和许可负责人。在担任该职务期间，索纳先生监督了所有促成该管道的交易制定活动，其中包括发现、技术、临床前和临床阶段交易，以及MRL风险投资基金。在加入默沙东之前，Thorner先生曾于2009年至2014年在诺华生物医学研究所担任交易、战略联盟主管，领导一个交易谈判人员团队，负责诺华公司（Novartis AG）或诺华（Novartis）的治疗管线的概念交易预验证。在加入诺华公司之前，Thorner先生曾于2003年至2009年在其法律和许可组织中担任安进的责任越来越大的职位。Thorner先生目前在Acesion Pharma AP担任董事会成员。在加入工业之前，Thorner先生在私人执业部门工作，就战略知识产权问题、许可协议、战略联盟和其他公司交易提供咨询。此外，他还担任美国联邦巡回上诉委员会尊敬的Randall R. Rader的书记员。Thorner先生拥有弗吉尼亚大学的法学博士和生物学硕士学位以及乔治梅森大学的学士学位。
- Benjamin Thorner has served as General Counsel and Chief Business Officer since 2021, overseeing all legal matters and deal making for Eikon. Prior to joining Eikon, Mr. Thorner served as Senior Vice President and Head of Business Development and Licensing for MRL from 2014 to 2021. In that role, Mr. Thorner supervised all deal making activities that contributed to the pipeline, which included discovery, technologies, preclinical and clinical stage deals, as well as the MRL Ventures Fund. Before Merck, Mr. Thorner served as Head of Transactions, Strategic Alliances at the Novartis Institutes for BioMedical Research from 2009 to 2014, leading a team of deal negotiators responsible for pre proof of concept deals for Novartis AG's, or Novartis', therapeutics pipeline. Prior to Novartis, Mr. Thorner held positions of increasing responsibility with Amgen in their legal and licensing organizations from 2003 to 2009. Mr. Thorner currently serves on the board of directors at Acesion Pharma ApS. Before joining the industry, Mr. Thorner worked in private practice providing counsel on strategic intellectual property issues, licensing agreements, strategic alliances, and other corporate transactions. In addition, he served as clerk to the Honorable Randall R. Rader, U.S. Court of Appeals for the Federal Circuit. Mr. Thorner holds a J.D. and master's degree in biology from the University of Virginia and a bachelor's degree from George Mason University.
- Michael Klobuchar
Michael Klobuchar自2024年起担任首席运营官。在这个职位上，他负责监督研究和工程职能，就像企业基础设施一样，包括全球供应链管理和产品制造、信息技术、设施以及整个企业的BINIS运营。Klobuchar先生是一名经过培训的化学工程师，其职业生涯跨越超过25年，在默沙东工作，在那里他通过该组织迅速崛起，在研发、制造、财务和公司战略领域担任高级领导职务。最近，Klobuchar先生在2021年至2024年期间担任默沙东的首席战略官，向首席执行官汇报工作，并担任默沙东执行委员会成员，负责推进和执行全球biness发展，领导数字化和数据转型，并监督这家全球企业的信息技术基础设施和网络安全战略。在担任此职务之前，他是MRL的高级副总裁、首席财务官以及投资组合和联盟管理主管，并领导该组织内的全球投资组合和联盟管理小组。Klobuchar先生目前担任Revvity，Inc.（NYSE：RVTY）的董事会成员，该公司是一家拥有11,000名员工的诊断和生命科学工具、仪器和软件提供商。Klobuchar先生分别拥有维拉诺瓦大学的工商管理硕士学位和罗格斯大学和普渡大学的化学工程硕士学位和学士学位。
Michael Klobuchar has served as Chief Operating Officer since 2024. In this role, he oversees research and engineering functions, as well as corporate infrastructure, including global supply chain management and product manufacturing, information technology, facilities, and business operations across the enterprise. A chemical engineer by training, Mr. Klobuchar's career spans more than 25 years with Merck where he rapidly rose through the organization to hold senior leadership roles across research and development, manufacturing, finance and corporate strategy. Most recently, Mr. Klobuchar served as Merck's Chief Strategy Officer from 2021 to 2024, reporting to the Chief Executive Officer and as a member of Merck's Executive Committee, and was responsible for the advancement and execution of global business development, led digital and data transformation, and oversaw the information technology infrastructure and cybersecurity strategies for the global enterprise. Prior to this role, he was Senior Vice President, Chief Financial Officer and Head of Portfolio and Alliance Management for MRL and led the Global Portfolio and Alliance Management group within that organization. Mr. Klobuchar currently serves on the board of directors at Revvity, Inc. (NYSE: RVTY), an 11,000 employee provider of diagnostics and life sciences tools, instruments, and software. Mr. Klobuchar holds a M.B.A. from Villanova University and M.S. and B.S. degrees in chemical engineering from Rutgers University and Purdue University, respectively.- Michael Klobuchar自2024年起担任首席运营官。在这个职位上，他负责监督研究和工程职能，就像企业基础设施一样，包括全球供应链管理和产品制造、信息技术、设施以及整个企业的BINIS运营。Klobuchar先生是一名经过培训的化学工程师，其职业生涯跨越超过25年，在默沙东工作，在那里他通过该组织迅速崛起，在研发、制造、财务和公司战略领域担任高级领导职务。最近，Klobuchar先生在2021年至2024年期间担任默沙东的首席战略官，向首席执行官汇报工作，并担任默沙东执行委员会成员，负责推进和执行全球biness发展，领导数字化和数据转型，并监督这家全球企业的信息技术基础设施和网络安全战略。在担任此职务之前，他是MRL的高级副总裁、首席财务官以及投资组合和联盟管理主管，并领导该组织内的全球投资组合和联盟管理小组。Klobuchar先生目前担任Revvity，Inc.（NYSE：RVTY）的董事会成员，该公司是一家拥有11,000名员工的诊断和生命科学工具、仪器和软件提供商。Klobuchar先生分别拥有维拉诺瓦大学的工商管理硕士学位和罗格斯大学和普渡大学的化学工程硕士学位和学士学位。
- Michael Klobuchar has served as Chief Operating Officer since 2024. In this role, he oversees research and engineering functions, as well as corporate infrastructure, including global supply chain management and product manufacturing, information technology, facilities, and business operations across the enterprise. A chemical engineer by training, Mr. Klobuchar's career spans more than 25 years with Merck where he rapidly rose through the organization to hold senior leadership roles across research and development, manufacturing, finance and corporate strategy. Most recently, Mr. Klobuchar served as Merck's Chief Strategy Officer from 2021 to 2024, reporting to the Chief Executive Officer and as a member of Merck's Executive Committee, and was responsible for the advancement and execution of global business development, led digital and data transformation, and oversaw the information technology infrastructure and cybersecurity strategies for the global enterprise. Prior to this role, he was Senior Vice President, Chief Financial Officer and Head of Portfolio and Alliance Management for MRL and led the Global Portfolio and Alliance Management group within that organization. Mr. Klobuchar currently serves on the board of directors at Revvity, Inc. (NYSE: RVTY), an 11,000 employee provider of diagnostics and life sciences tools, instruments, and software. Mr. Klobuchar holds a M.B.A. from Villanova University and M.S. and B.S. degrees in chemical engineering from Rutgers University and Purdue University, respectively.
- Roger M. Perlmutter
Roger M. Perlmutter自2013年4月起担任默克制药公司负责默克研究实验室的执行副总裁及总裁，管理全球公司的研究和开发。于2001年1月成为安进公司研发执行副总裁。从1999年7月到2000年12月，他担任Merck研究实验室全球基础研究和临床前开发的执行副总裁。从1999年2月到1999年7月，他担任默克研究实验室的执行副总裁，从1997年2月到1999年1月担任默克研究实验室的高级副总裁。从1989年5月到1997年1月，他也是华盛顿大学免疫学系的主席，从1991年1月到1997年1月，华盛顿大学免疫、生物化学和医学系的教授。从1984年7月到1997年1月，他担任华盛顿大学霍华德休斯医学研究所的研究员。他目前任职于StemCells, Inc.的董事会。
Roger M. Perlmutter has served as Chief Executive Officer and Chair and a member of board of directors since 2021. Dr. Perlmutter is a highly accomplished industry and academic leader with more than 35 years of experience. Prior to joining Eikon Therapeutics, Inc., Dr. Perlmutter was Executive Vice President of Merck and President of Merck Research Laboratories, or MRL, from 2013 to 2020, where he supervised the discovery and development of numerous lifesaving medicines including pembrolizumab, Merck's foundational immuno oncology therapeutic. Before his time at Merck, Dr. Perlmutter spent twelve years as Executive Vice President and Head of Research and Development at Amgen, where he supervised the development of important biopharmaceuticals for the treatment of osteoporosis and cancer related bone disease and for the reduction of hypercholesterolemia related cardiovascular risk. Prior to Amgen, Dr. Perlmutter served as Executive Vice President of Basic and Preclinical Research at MRL from 1997 to 2001. Prior to assuming leadership roles in the industry, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry, and Medicine at the University of Washington, Seattle and also served as Chairman of its Department of Immunology, where he was at the same time an investigator of the Howard Hughes Medical Institute. His research focused on understanding the signaling pathways that control lymphocyte activation. Prior to his role at the University of Washington, he was a lecturer in the Division of Biology at the California Institute of Technology, Pasadena. Dr. Perlmutter is an elected member of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, and both a distinguished fellow and past president of the American Association of Immunologists. Dr. Perlmutter currently serves on the board of directors at Insitro, Inc. and NGM Biopharmaceuticals, Inc. Dr. Perlmutter holds an M.D. and a Ph.D. from Washington University in St. Louis and a bachelor's degree from Reed College.- Roger M. Perlmutter自2013年4月起担任默克制药公司负责默克研究实验室的执行副总裁及总裁，管理全球公司的研究和开发。于2001年1月成为安进公司研发执行副总裁。从1999年7月到2000年12月，他担任Merck研究实验室全球基础研究和临床前开发的执行副总裁。从1999年2月到1999年7月，他担任默克研究实验室的执行副总裁，从1997年2月到1999年1月担任默克研究实验室的高级副总裁。从1989年5月到1997年1月，他也是华盛顿大学免疫学系的主席，从1991年1月到1997年1月，华盛顿大学免疫、生物化学和医学系的教授。从1984年7月到1997年1月，他担任华盛顿大学霍华德休斯医学研究所的研究员。他目前任职于StemCells, Inc.的董事会。
- Roger M. Perlmutter has served as Chief Executive Officer and Chair and a member of board of directors since 2021. Dr. Perlmutter is a highly accomplished industry and academic leader with more than 35 years of experience. Prior to joining Eikon Therapeutics, Inc., Dr. Perlmutter was Executive Vice President of Merck and President of Merck Research Laboratories, or MRL, from 2013 to 2020, where he supervised the discovery and development of numerous lifesaving medicines including pembrolizumab, Merck's foundational immuno oncology therapeutic. Before his time at Merck, Dr. Perlmutter spent twelve years as Executive Vice President and Head of Research and Development at Amgen, where he supervised the development of important biopharmaceuticals for the treatment of osteoporosis and cancer related bone disease and for the reduction of hypercholesterolemia related cardiovascular risk. Prior to Amgen, Dr. Perlmutter served as Executive Vice President of Basic and Preclinical Research at MRL from 1997 to 2001. Prior to assuming leadership roles in the industry, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry, and Medicine at the University of Washington, Seattle and also served as Chairman of its Department of Immunology, where he was at the same time an investigator of the Howard Hughes Medical Institute. His research focused on understanding the signaling pathways that control lymphocyte activation. Prior to his role at the University of Washington, he was a lecturer in the Division of Biology at the California Institute of Technology, Pasadena. Dr. Perlmutter is an elected member of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, and both a distinguished fellow and past president of the American Association of Immunologists. Dr. Perlmutter currently serves on the board of directors at Insitro, Inc. and NGM Biopharmaceuticals, Inc. Dr. Perlmutter holds an M.D. and a Ph.D. from Washington University in St. Louis and a bachelor's degree from Reed College.